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Abstract 
Haemochromatosis is an inherited disease in which the body absorbs iron at an 
accelerated rate, leading to iron overload and oxidative damage. This occurs in major 
organs such as the liver, heart and pancreas but may also occur in the brain. The brain 
has a high iron requirement and few antioxidants compared to the rest of the body, 
making it particularly vulnerable to oxidative stress. Brain iron overload has been 
implicated in the pathogenesis and progression of diseases such as Multiple Sclerosis, 
Parkinson's Disease and Alzheimer's Disease. Case studies have investigated patients 
who have both haemochromatosis and altered cognitive functioning, although most 
have involved patients with advanced disease and additional complications, making it 
difficult to establish causation. If iron-mediated damage occurs within the brain in 
people with haemochromatosis then it is possible that processes such as memory, 
learning, attention and information processing speed are affected. These processes are 
sensitive to brain damage and are commonly influenced by concussion and metabolic 
disorders. Separating the primary effects of iron overload from secondary effects such 
as anxiety, depression, fatigue and pain is difficult as each impacts on cognition. 
Many people with haemochromatosis have complained of cognitive problems. 
However medical staff have attributed these problems to secondary effects of the 
disease. No study to date has attempted to investigate the primary effects of 
haemochromatosis on cognitive functioning using comprehensive neuropsychological 
tests and a large patient sample with matched controls. 
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Introduction 
Many people with haemochromatosis report cognitive problems, particularly 
problems with memory, as a symptom of their disease. While these complaints have 
often been dismissed by health professionals as resulting from fatigue or depression, 
there is evidence that iron-mediated damage within the brain may be responsible. This 
paper aims to explore that possibility beginning with describing hereditary 
haemochromatosis, the roles of iron within the body and the processes by which iron 
is absorbed and distributed. The alterations in iron absorption and distribution that 
occur in haemochromatosis are outlined, as well as connections between excess iron 
and pathology such as Alzheimer's Disease. The cognitive processes that may be 
affected by iron-mediated damage — attention, processing speed, learning and memory 
- are outlined. The difficulties in measuring these processes in people who experience 
other symptoms that are known to affect cognition such as fatigue, pain, depression 
and anxiety are also discussed. 
Haemochroinatosis: An Overview 
Description and Diagnostic Features 
Hereditary haemochromatosis is an autosomal recessive disease in which dietary iron 
is absorbed at 2-3 times the normal rate. Because iron is not readily excreted, except 
through blood loss (Pietrangelo, 2003), this excess iron accumulates in major organs, 
leading to oxidative damage and cell death. The pattern of damage varies from person 
to person but the liver, heart, brain, pancreas and joints are commonly affected. 
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The initial symptoms of haemochromatosis are often vague such as a general feeling 
of illness or fatigue. Subsequent symptoms are specific to organ damage and include 
arthritis, abdominal pain, weight loss or weight gain, heart arrhythmia, elevated blood 
sugar levels, bronzed skin, liver problems, impotence and hypothyroidism (Milder, 
Cook, Stray & Finch, 1980). Secondary effects of iron overload include depression, 
fatigue, diabetes, heart disease, cirrhosis of the liver, cancer, infertility and 
neurological problems (Powell, George, McDonnell & Kowdley, 1998). 
Hereditary haemochromatosis is caused by a mutation in the HFE gene but diagnosis 
also depends on the expression of clinical symptoms (Pietrangelo, 2003). Factors such 
as diet, gender, age, alcohol intake and co-morbid health problems mediate disease 
expression. While it is currently impossible to predict who will develop symptoms 
and when (Pietrangelo, 2004), the majority (70%) of people with hereditary 
haemochromatosis will develop symptoms of iron overload in the third to fifth decade 
of life (Fletcher & Halliday, 2002). Men generally develop symptoms earlier than 
women as women are protected from iron overload by menstruation and pregnancy. 
The C282Y mutation 
The HFE mutation, named C282Y, is thought to have occurred approximately 2000 
years ago but was discovered in 1996 by Feder and his colleagues (Rankin, Baxter, 
Valentine & Powell, 2001; Wood, 2002). The 'recessive' nature of the C282Y 
mutation means that one gene mutation from each parent must be inherited in order to 
acquire haemochromatosis (Bassett et al., 1992). Carriers (people with one normal 
and one mutated HFE gene) often have elevated iron levels but generally do not 
develop significant health problems. Prevalence rates for the C282Y mutation in 
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Australia are estimated to be 3.6 per 1000 and 12% of Australians are estimated to be 
carriers (Bassett et al., 1992). 
Importance of early diagnosis and treatment 
Early diagnosis of haemochromatosis is essential to promote both quality of life and 
longevity. The non-specific nature of symptoms and their association with many other 
diseases makes diagnosis based on symptoms alone extremely difficult (Bomford, 
2002). Early diagnosis depends on routine iron-level testing and genetic testing of 
family members (Brandhagen et al., 2002). 
The recommended treatment for haemochromatosis is regular venesection — the 
removal of approximately 500m1 of blood - to stabilise iron levels (Bassett et al., 
1992). Treatment can prevent and/or alleviate symptoms of iron overload. Without 
treatment, organ damage continues and symptoms worsen (Bassett et al., 1992). 
Venesection is not recommended in the few situations where losing blood would 
impact on other health problems. In these cases an iron-chelating drug, Deferoxamine, 
may be used (Emerit, Beaumont & Trivin, 2001). 
Iron and the Body 
Iron is an essential nutrient for almost all living organisms. It has the ability to readily 
accept or donate electrons, making it integral to the transportation of oxygen around 
the body. However, the potentially reactive nature of iron means that it can 
"...damage tissue by catalysing the conversion of hydrogen peroxide into free-radical 
ions that attack cellular membranes, protein and DNA." (Emerit et al., 2001, p. 333). 
To prevent the formation of free radicals, iron levels are carefully regulated (Emerit et 
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al., 2001). Transferrin and ferritin are iron-binding proteins that transport and store 
iron safely. Iron regulatory proteins bind to transferrin and ferritin and act to inhibit or 
facilitate their actions according to the body's needs. Knowledge of how these work, 
and whether other iron regulatory proteins, transporter proteins or iron sensory 
elements exist is yet unknown (Lieu, Heiskala, Peterson & Yang, 2001). 
The body's main source of iron is recycled iron (Pietrangelo, 2003) - iron is 
transported within the bloodstream to bone marrow where erythrocytes (red blood 
cells) are produced. When these are destroyed they are consumed by 
reticuloendothelial cells, which release iron back into the bloodstream. 
Body iron levels are controlled through regulating the uptake of dietary iron 
(Pietrangelo, 2003). Crypt cells in the intestine receive information regarding current 
iron stores and needs. As they mature into absorptive enterocytes, they regulate iron 
uptake by expressing more or less iron-transport receptors on their surface (Fleming 
& Sly, 2002). 
Iron absorption and haemochromatosis 
How the HEE mutation leads to increased absorption of dietary iron is not fully 
understood. Most of the knowledge in this area is derived from studies of cultured 
cells and from genetically modified mice (Fleming & Sly, 2002). In healthy people 
the HFE protein associates with transferrinl receptors (Fleming & Sly, 2002) and 
both are expressed on the surface of cells (Pietrangelo, 2003). This combination is 
thought to play a major role in iron uptake, particularly in enterocytes (Fleming & 
Sly, 2002). The transferrin/iron/HFE complex is internalised by the cell and separated 
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in the endosome. Transferrin is recycled to the cell's surface and iron is used 
immediately or stored as ferritin; the fate of HFE at this stage is unknown (Fleming & 
Sly, 2002). 
The C282Y mutation results in inadequate HFE expression on the cell's surface and 
hence a reduction in transferrin-mediated iron uptake, leading to iron deprivation 
within the cell. Future crypt cells are then programmed to absorb more iron to correct 
this deficit (Fleming & Sly, 2002). The new crypts absorb iron through non-
transferrin pathways such as divalent metal transport 1 protein (DM11). As their 
internal iron levels increase, they export more iron into the bloodstream (Fleming & 
Sly, 2002). Reticuloendothelial cells are also reported to up-regulate their iron intake 
and release more iron into the bloodstream (Pietrangelo, 2004). 
Hepicidin, a liver peptide, has recently been implicated in iron overload in 
haemochromatosis (Limdi & Crampton, 2004). Hepicidin is thought to relay 
information about body iron stores to both enterocytes and reticuloendothelial cells 
via the HFE/transferrin pathway and is particularly important in reducing iron uptake. 
The expression of hepicidin is significantly decreased in mice that are HFE deficient 
(Pietrangelo, 2004). 
While this is only one hypothesis of how iron absorption is modified in 
haemochromatosis, it is the one most supported by current evidence. More studies are 
required to confirm these findings (Fleming & Sly, 2002). 
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Iron and the Brain 
Importance of iron in brain function 
It was once thought that iron did not cross the blood brain barrier (BBB) and therefore 
could not affect brain functioning in people with hemochromatosis (Sachdev, 1993). 
It is now known that iron does cross the BBB and it is likely that there is a dynamic 
exchange of iron between organs, including the brain. This system allows iron to be 
quickly transferred from other organs to the brain when iron levels are low (Connor, 
Menzies, Joseph, Burdo & Boyer, 2001a). 
Within the brain, iron is involved in "...oxygen transport, electron transport, glucose 
metabolism, and the synthesis of neurotransmitters, myelin, and DNA replication..." 
(Pinero & Connor, 2000, p. 435). Areas of the brain that are rich in iron are also rich 
in dopamine, GABA and serotonin receptors and when iron levels are low there is a 
decrease in both GABA, glutamate, and dopamine receptor expression (Sachdev, 
1993). The brain has a high iron requirement (Pinero & Connor, 2000) and iron 
deficiency causes cell loss and decreased function within the brain, with significant 
and long-lasting effects on learning and cognitive and motor functioning in both 
children and adults (Burdo & Connor, 2002). 
Iron Transport and the Brain 
The blood-brain barrier poses specific challenges to the transportation of iron to and 
from the brain. The various regions, functions and cell types that exist within the 
brain, in addition to changing developmental iron needs, also complicate iron 
homeostasis (Connor et al., 2001a). 
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Iron uptake within the brain is mediated by transferrin receptor expression. 
Transferrin receptors have been found on the BBB (Connor et al., 2001a) and some 
studies have found that the iron-transferrin complex is transported across the BBB. 
However, more iron than transferrin crosses the BBB, indicating that additional 
transport mechanisms are involved (Connor et al., 2001a). DMT1 is thought to be 
involved in iron transportation to the brain. Belgrade rats, which have a defect in 
DMT1, have very low brain iron levels (Connor et al., 2001a). In humans, DMT1 
occurs in neurons within the striatum, thalamus, choroid plexus and the cerebellum 
(Pinero & Connor, 2000). DMT1 has also been found in the blood vessels that line the 
brain, the choroid plexus and cells lining the brain/ventricle interface (Connor et al., 
2001a). 
A third iron-transport protein, lactoferrin, also occurs in the brain. Lactoferrin is part 
of the transferrin family but has a greater binding capacity than transferrin 
(Thompson, Shoham & Connor, 2001). Occurring in milk, mucosal tissues and 
leukocytes (Powell & Halliday, 1985), it has also been found in neurons, brain 
vasculature (Thompson et al., 2001) and the substantia nigra (Connor et al., 2001a). 
Its expression is increased in patients with Parkinson's Disease (Burdo & Connor, 
2002; Pinero & Connor, 2000) in association with increased intraneuronal iron levels 
and degeneration of dopaminergic neurons within the substantia nigra. 
Iron is also transported to areas of the brain outside the BBB such as the posterior 
pituitary and median eminence. Tanycytes, glial cells that line the ventricles, are 
thought to play a role in transporting iron to these areas (Connor et al., 2001a) as these 
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cells surround the circumventricular areas and stain heavily for iron and ferritin 
(Pinero & Connor, 2000). 
Iron is distributed within the brain via cerebrospinal fluid (CSF). The choroid plexus 
manufactures transferrin and releases iron-laden transferrin into CSF (Connor et al., 
2001a). Transferrin saturation levels within CSF vary but have been reported at full 
capacity. Other iron transport systems within CSF include proteins such as citrate, 
adenosine triphosphate (Cheepsunthorn, Palmer, Menzies, Roberts & Connor, 2001), 
ascorbate and ferritin (Burdo & Connor, 2002). 
Iron recycling also occurs in the brain. Microglia obtain iron through phagocytosis 
and release iron to oligodendrocytes for myelin production. Oligodendrocytes also 
sequester excess iron to microglia, which can be regained if brain damage occurs 
(Connor et al., 2001a). 
Regional Brain Iron 
Iron levels are highest in areas of the brain that are associated with motor functions 
such as the motor cortex, basal ganglia and other subcortical structures (Connor et al., 
2001a). These areas are involved in translating cognitions into actions, initiating and 
maintaining movement, developing habits and skills and procedural memory (Lezak, 
Howieson & Loring, 2004). The substantia nigra and the globus pallidus have high 
iron levels but low transferrin densities (Pinero & Connor, 2000; Sachdev, 1993) and 
are connected to the nucleus accumbens and the caudate putamen, which have low 
iron levels and high transferrin receptor densities. It is thought that the areas abundant 
in transferrin receptors deliver iron to areas that have few transferrin receptors. 
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White matter, which transmits neural impulses within and between cortical and 
subcortical areas (Lezak et al., 2004), has the highest concentration of iron in the 
brain. Oligodendrocytes require large amounts of iron for the production and 
maintenance of myelin (Pinero & Connor, 2000), which enhances conduction speed. 
Oligodendrocytes rely primarily on ferritin for their iron requirements (Burdo & 
Connor, 2002). While oligodendrocytes are most prevalent in white matter, they also 
occur in the substantia nigra and striatum (Connor et al., 2001a). 
Ferritin plays an important role within the brain as an iron storage system. Ferritin has 
a high iron-binding capacity and sequesters excess iron during traumatic events such 
as hypoxia and seizures. H-type ferritin is a fast-acting system, able to sequester and 
release iron quickly, whereas L-ferritin is a slower-acting, longer-term storage system 
(Cheepsunthorn et al., 2001). Ferritin is found mainly within white matter and the 
cortex (Pinero & Connor, 2000). 
Iron Efflux from the Brain 
Inadequate efflux may be responsible for some types of iron-mediated damage within 
the brain (Connor et al., 2001a). Little is known about how brain iron efflux occurs 
(Burdo & Connor, 2002; Connor et al., 2001a), however it has been demonstrated that 
iron can be transported across the ventricle lining into the bloodstream (Burdo & 
Connor, 2002). Ceruloplasmin is an endogenous iron cheater that may facilitate iron 
efflux from the brain (Thompson et al., 2001). In animals, iron efflux occurs in a 
regionally specific pattern that changes according to developmental stage. If 
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inadequate iron efflux is the cause of iron overload, some areas may be more 
susceptible to damage than others (Connor et al., 2001a). 
Evidence for Increased Brain Iron in Haemochromatosis 
In the 1930's and 1940's, brain iron levels were investigated post-mortem in people 
with haemochromatosis. Iron levels were not found to be elevated in areas that were 
protected by the BBB (Sachdev, 1983). However, techniques have become more 
sophisticated over time and recent results from MRI, CT and transcranial sonography 
have suggested that brain iron levels can be abnormally high in people with 
haemochromatosis, particularly within the basal ganglia (Burdo & Connor, 2002; 
Connor et al., 2001a; Pinero & Connor, 2000). 
The HFE protein has been found to associate with transferrin receptors in the choroid 
plexus, brain capillaries and ependymal cells. The aforementioned increase in iron 
uptake that occurs in the intestine due to the HFE mutation may also occur in the 
brain (Connor et al., 2001b). Areas of the brain that are highest in transferrin receptors 
include the cortex, amygdala, hippocampus and the brainstem (Pinero & Connor, 
2000) which are broadly involved in awareness and behaviour, emotional processing, 
attention and learning, memory, and consciousness and arousal, respectively (Lezalc, 
1995). An experiment with HFE-gene modified mice found significantly elevated 
brain iron levels at 20 weeks of age compared to controls (Connor et al., 2001a). 
These findings indicate that iron accumulates at an accelerated rate in the brains of 
mice with haemochromatosis. It is unknown whether these findings generalise to 
humans. 
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Iron and neurodegenerative diseases 
The brain naturally has high iron levels (Connor et al., 2001b; Pinero & Connor, 
2000) and few antioxidants compared to the rest of the body, making it particularly 
vulnerable to oxidative damage (Connor, Snyder, Arosio, Loeffler, & DeWitt, 1995; 
Thompson et al., 2001). Iron overload and oxidative damage has been implicated in 
the pathogenesis and progression of many neurodegenerative diseases, particularly 
movement disorders, and iron overload is prominent in areas of the brain associated 
with motor control (Burdo & Connor, 2002). Below is a brief summary: 
Disease 
Fredreich's ataxia 
Symptoms: Ataxia, motor weakness, 
proprioceptive loss, dysarthria 
Increased iron in: Dentate nucleus 
& mitochondria 
Studies/Reviews 
Burdo & Connor, 2002 
Connor et al., 2001a 
Pinero & Connor, 2000 
Lieu et al., 2001 
Thompson et al., 2001 
Parkinson's Disease 
Symptoms: Rigidity, tremor, bradykinesia 
death of dopaminergic neurons 
Increased iron in: Substantia Nigra, 
striatum, Lewybodies 
Burdo & Connor, 2002 
Connor et al., 2001a 
Connor et al., 1995 
Gerlach, Ben-Schadar 
Riederer & Youdim, 1994 
Lieu et al., 2001 
Pinero & Connor, 2000 
Sachdev, 1993 
Thompson et al., 2001 
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Multiple Sclerosis 
Symptoms: Fatigue, weakness, 
dysarthria, sensory changes 
Increased iron in: Oligodendrocytes 
Huntington 's Disease 
Symptoms: Cognitive, motor and 
psychiatric disturbance 
Increased iron in: Striatum 
Hallervorden-Spatz Syndrome 
Symptoms: Extra pyramidal dysfunction 
rigidity, dystonia, choreathetosis 
Increased iron in: Substantia Nigra, 
globus pallidus 
Burdo & Connor, 2002 
Connor et al., 2001a 
Pinero & Connor, 2000 
Thompson et al., 2001 
Burdo & Connor, 2002 
Connor et al., 2001a 
Gerlach et al., 1994 
Pinero & Connor, 2000 
Burdo & Connor, 2002 
Connor et al., 2001a 
Jones & Hedley-Whyte, 1983 
Lieu et al., 2001 
Pinero & Connor, 2000 
Thompson et al., 2001 
The role of iron in Alzheimer's Disease will be explored in more detail, as it is most 
relevant to this study. 
Iron and Alzheimer's Disease 
Alzheimer's Disease (AD) is characterised by a progressive deterioration in memory, 
personality and intellectual ability. This is associated with neuronal death and the 
formation of amyloid plaques and neurofibrillary tangles in cortical and sub-cortical 
areas (Gerlach et al., 1994). Excess iron within the brain is a consistent finding in 
people with AD (Connor et al., 2001b) and it is hypothesised that iron overload may 
be a risk factor for AD (Connor et al., 2001a). 
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In AD, iron levels are reportedly increased in the hippocampus, prefrontal cortex, 
amygdala, frontal lobes, inferior parietal lobes, temporal cortex, nucleus basalis, 
globus pallidus and the motor cortex. Iron levels are decreased in the occipital cortex 
and substantia nigra (Pinero & Connor, 2000; Sachdev, 1993). Elevated iron levels 
are present in the basal ganglia at the point of onset of AD and therefore iron 
accumulation is thought to play a role in the pathogenesis of the disease (Burdo & 
Connor, 2002; Lieu et al., 2001). 
Increased iron is associated with neuritic plaques that are the hallmark of AD (Connor 
et al., 2001a; Connor et al., 2001b). Changes in iron homeostasis are thought to 
influence the production of amyloid — the key component of the plaques (Burdo & 
Connor, 2002; Thompson et al., 2001) - and increased iron promotes the deposition 
of plaques in vitro (Connor et al., 2001b). Iron is also found in neurons that contain 
neurofibrillary tangles (Pinero & Connor, 2000) and may play a role in their 
formation (Thompson et al., 2001). 
Iron regulatory proteins maintain iron homeostasis within the brain by controlling the 
expression of transferrin and ferritin. Iron Regulatory Protein 2 (1RP2) is found in 
intraneuronal lesions, senile plaques and neurofibrillary tangles (Lieu et al., 2001) and 
its expression is altered in AD (Pinero & Connor, 2000). This alteration leads to an 
up-regulation of transferrin receptors and a down-regulation of ferritin, resulting in 
cells increasing their iron uptake without the capacity to store it safely. Iron 
accumulates faster than ferritin production in regions of the brain that have the highest 
rates of degeneration in people with AD, whereas areas that have equal ferritin-iron 
levels are relatively spared (Burdo & Connor, 2002). In healthy brains, ferritin levels 
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increase linearly with iron levels and sequester excess iron to protect cells (Lieu et al., 
2001; Pinero & Connor, 2000). 
Treatments for AD have included iron-chelating drugs such as deferoxamine. These 
have been successful in reducing iron levels and slowing progression of AD (Pinero 
& Connor, 2000; Sachdev, 1993). The administration of anti-oxidants such as vitamin 
E, oestrogen and selegiline also delay the onset of AD (Connor et al., 2001b; Sano, 
2003), providing further evidence that iron-induced oxidative damage contributes to 
the pathology of AD. 
Cognitive Functions that may be Impaired 
Cognitive Problems Resulting from Iron Overload 
Because iron crosses the BBB and excess iron can accumulate in the brain, cognitive 
processes are likely to be affected in people with haemochromatosis. Those that are 
most sensitive to brain damage include memory, learning, information processing 
speed and attention. These functions are frequently impaired by diffuse brain damage 
such as concussion and metabolic disorders (Lezak et al., 2004). While all of these 
functions are "...inextricably bound together — different facets of the same thing." 
(Lezak et al., 2004, p. 20), they will be described separately. 
Information Processing and Attention 
Information processing speed is the rate at which the nervous system can convey 
messages (Gronwall & Sampson, 1974). Reduced information processing speed 
affects many other areas of cognition including attention, learning and memory 
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(Felmingham, Baguley & Green, 2004). The mechanisms underlying information 
processing speed are not known, although diffuse brain damage is frequently the 
cause of processing speed deficits (Felmingham et al, 2004; Gronwall & Sampson, 
1974). Descriptions of information processing often underlie or overlap with 
descriptions of attention (van Zomeren & Spikman, 2003; Vlaar & Wade, 2003). 
There are many definitions of attention. It is a resource that filters incoming 
information, selects certain inputs for processing, and processes information 
(Eccleston & Crombez, 1999). It can be conceptualised as a cognitive spotlight that 
can be directed at something to focus on it in more detail. Its scope can be widened 
but this causes its brightness to be diminished, as its overall capacity is limited 
(Lieberman, 2004). 
Attentional tasks are those that require planning, decision making, learning new 
sequences, responding to new or dangerous stimuli, or overcoming a habitual activity 
or response (Norman & Shallice, 1986). Many operations can be performed 
automatically with limited attentional control (Eccleston, 1994). Attention has many 
facets - divided attention, sustained attention, selective attention and focused attention 
- and while these can never be completely separated from each other, tests of attention 
generally focus one of these aspects (Rogers, 2000; van Zomeren & Spikman, 2003). 
Deficits in attention and information processing affect other cognitive processes such 
as memory and learning because information must be attended to and processed 
before it can be retained. The most sensitive tests of attention and information 
processing deficits are speed-based tests. The Stroop colour word task, Paced 
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Auditory Serial Addition Test (PASAT), Information Processing Task A and choice 
reaction time tasks are all speed-based and measure various aspects of attention and 
information processing speed. 
Memory and Learning 
Learning is defined as the ability to acquire knowledge, while memory is the ability to 
retain it (Lieberman, 2004). However the two processes are dependent on each other 
and at times difficult to separate so they will be considered together. 
Memory consists of encoding (recording an experience by making an internal 
representation of it), storage (holding that experience over time), and retrieval (when 
the remembered information is used in some way) (Lieberman, 2004). A number of 
models of memory have been proposed and only a few will be discussed. The 
Atkinson-Shiffrin model includes three separate memory systems that work together: 
sensory memory stores a vast amount of information in a buffer of very short-term 
capacity and transfers a small amount of this into short-term memory. Short-term 
memory holds approximately seven pieces of information for around 30 seconds. 
Some of this information is then transferred to long-term memory, which holds an 
infinite amount of information for a seemingly unlimited time (Liberman, 2004). 
The concept of short-term memory was further developed by Baddeley (1986) who 
proposed that it is more than just a storage system. Baddeley and Hitch devised a 
model of 'working memory' that consists of a central executive control centre and 
two slave systems: an articulatory loop specialised for processing language, and a 
visual-spatial sketchpad for retention of visual and spatial material (Baddeley, 1986). 
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The visual-spatial component has since been divided into separate visual and spatial 
systems (Della Salla, Gray, Baddeley, Allamano & Wilson, 1999). The central 
executive is able to process information from many sources, possesses attentional 
resources and can select and operate different control processes to aid problem 
solving and decision-making (Baddeley, 1986). The central executive is the least 
investigated aspect of working memory and, as such, little is known about its 
functions (Lieberman, 2004). 
Tasks that are frequently used to measure memory include recalling previously 
presented word lists, complex designs, pictures, numbers or stories. Tests of working 
memory involve maintaining a number of items in short term memory while 
performing concurrent processes such as counting or problem solving (Gavens & 
Barrouillet, 2004). The more demanding the processing component (ie the more 
attentional resources required), the less information is remembered. 
Forgetting can be attributed to losing previously attained information. However, it 
may be more likely that the information is just difficult to retrieve. When cues are 
given regarding the 'forgotten' information, recall is enhanced. Recognition tasks, 
where cues are given regarding previously presented information, elicit greater 
amounts of information than recall tasks, where no cues are given (Lieberman, 2004). 
Other factors affecting cognitive processes 
Cognitive processing is affected by factors other than organic damage. Anxiety, 
depression, fatigue and pain can all adversely impact on cognition and are common 
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outcomes of brain injury and disease (Lezak et al., 2004). Depression and fatigue are 
particularly common symptoms of haemochromatosis (Sachdev, 1993). 
Pain 
Many studies have investigated the effects of cognition on pain, however few studies 
have focused on the effects of pain on cognition (Grigsby, Rosenberg & Busenbark, 
1995). The complex nature of pain makes measurement and interpretation difficult as 
secondary changes in mood, sleep and lifestyle mediate the effects of pain on 
cognition (Ziegler & Paolo, 1995). 
For example, Grace, Nielson, Hopkins & Berg (1999) found that fibromyalgia 
patients performed more poorly than matched controls on the PASAT and measures 
from the Wechsler Memory Scale — Revised, however, cognition was more related to 
sleep quality and anxiety levels than to pain intensity. Iezzi, Duckworth, Vuong, 
Archibald and Klinck (2004), using a regression analysis, found that pain severity was 
a significant predictor of memory scores as measured by the Wechsler Memory Scale-
Revised, independent of its secondary effects. However, in this study secondary 
effects were measured only by the SCL-90. Bell, Primeau, Sweet and Lofland (1999) 
found no negative effects of pain on cognition, although these results were based on 
comparisons with test norms rather than a matched control group. Overall, most 
studies have found that participants with severe pain demonstrate impairments on 
measures of attentional capacity, processing speed and psychomotor speed (Hart 
Martelli & Zasler, 2000, Martelli, Grayson & Zasler, 1999) although non-clinical pain 
has little effect on cognitive functioning (Hart et al., 2000, Ziegler & Paolo, 1995). 
19 
Pain is a powerful stimulus and indicates danger (Grigsby et al., 1995). It therefore 
interrupts other cognitive activities and is difficult to disengage from (Eccleston & 
Crombez, 1999). Apkarin, Sosa and Krauss et al. (2004) proposed that chronic pain 
impacts on other cognitive processes because it competes successfully for cognitive 
resources. 
The findings from studies of clinical pain may not generalise to patients with 
haemochromatosis. It is unlikely that the majority of people with haemochromatosis 
would experience pain that is severe enough to impact on cognitive functioning. 
However, the secondary changes in mood and lifestyle associated with chronic pain 
that influence cognitive functioning may affect people with haemochromatosis. 
Fatigue 
Few studies have investigated the impact of fatigue on cognitive functioning (Short, 
McCabe & Tooley, 2002). The majority of research has focused on cognitive 
functioning in patients with Chronic Fatigue Syndrome (CFS) (Dobbs, Dobbs & Kiss, 
2001). 
Studies of CFS patients have yielded conflicting results. Some have found deficits in 
information processing speed (Bushio, Tiersky, Deluca & Natelson, 2004; Deluca, et 
al., 2004), attention and motor speed (Bushio et al., 2004) compared to matched 
controls, with negative findings on tests of memory and executive functioning. Other 
studies have found significant deficits in learning, memory (Marcel, Komaroff, 
Fagioli, Kornish & Albert, 1996) and executive functioning (Dobbs et al., 2001) 
compared to matched controls, with no between-group differences in attention 
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(Marcel et al., 1996). The most consistently documented cognitive deficits in review 
papers include complex information processing efficiency and speed (Michiels & 
Cluydts, 2001; Tiersky, Johnson, Lange, Natelson & DeLuca, 1997) and working 
memory and learning (Michiels & Cluydts, 2001). 
Using individual rather than group comparisons, Vercoulen, Bazelmas, Swanink, 
Galama and Fennis (1998) found that only a subgroup (approximately 30%) of 
patients with CFS demonstrated impairments in cognitive functioning, with the 
majority performing within the average range. This may explain the discrepant 
findings between studies. Although patients with CFS tend to express high levels of 
psychological distress, this does not seem to fully account for their performance on 
cognitive tests (Crowe & Casey, 1999; Daly, Komaroff, Bloomingdale, Wilson & 
Albert, 2001; Kane, Gants & DiPino, 1997; Marcel et al., 1996; Short et al., 2002; 
Vercoulen et al., 1998). 
The results from studies of CFS may not generalise to other diseases such as 
haemochromatosis as factors other than fatigue may account for differences in 
cognitive functioning. The heterogeneity of CFS even makes comparisons between 
populations from different studies and generalisations to the wider CFS population 
difficult. 
Depression 
Depression frequently co-occurs with chronic diseases such as haemochromatosis. It 
is widely accepted that cognitive deficits occur in people with major depression 
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(Naismith et al., 2003; Veiel, 1997) although studies of different cognitive processes 
have yielded mixed results (Airaksinen, Larsson, Lundberg & Forsell, 2004). 
Veiel (1997) conducted a meta-analysis of methodologically sound studies comparing 
younger adults (aged from 20's to 50's) meeting DSM III criteria for major 
depression to matched controls on a variety of cognitive measures. 
The majority of studies found no significant differences between depressed samples 
and controls on measures of attention and concentration, as assessed primarily by 
digit span or block span tasks (Veiel, 1997). A small proportion of depressed 
individuals (11%) scored within the defective range on tests of verbal fluency, 
primarily measured by the Controlled Oral Word Association Test. Measures of visual 
and spatial functions - such as the Complex Figure Test, Block Design and Object 
Assembly - and measures of non-verbal learning for visually presented material 
indicated that approximately 15% of depressed patients experienced difficulties 
compared to controls. Tests of verbal learning and memory yielded similar results 
with 14-15% of depressed patients scoring within the defective range on tests of 
paired associations, list learning and story recall (Veiel, 1997). 
The most prominent effects of depression on cognitive functioning were noted on 
tests of 'mental flexibility and control' which are sensitive to brain dysfunction. A 
total of 50% of depressed participants scored within the defective range on these 
tasks. Reaction times were also impaired (Veiel, 1997). 
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Elderkin-Thompson, Kumar, Bilker, et al. (2003) and Airaksinen et al. (2004) 
assessed the impact of depression severity on cognitive processing in older and 
younger population samples, respectively. Participants with major depression tended 
to perform more poorly than participants with minor depression, with healthy controls 
eliciting the highest scores on measures of verbal skills and maintenance of set 
(Elderkin-Thompson et al., 2003). Episodic memory scores differentiated the major in 
Airaksinen et al.'s study. 
Weiland-Feidler et al. (2004) found that depression has long-lasting effects on 
sustained attention, even when the depressive episode has ceased. However visual and 
verbal memory, learning and attention set-shifting appear to be state-dependent. 
Rohling, Green, Allen and Iverson (2002) investiged the relationship between self-
reported depression and cognitive functioning, and found no significant relationship 
between reported symptoms and actual deficits on a wide range of cognitive tests. 
Rohling et al. also expected participants with higher levels of depression to perform 
more poorly on tests that required more mental effort (as opposed to automatic 
processing). Again, no significant relationship was found between the amount of 
effort required and performance deficits. Rohling et al. (2002) had excluded patients 
who failed symptom validity tests, and concluded that this may why their findings 
differed from the studies that they aimed to replicate — none of their patients were 
'faking bad', which may be the case in other studies using depressed samples. 
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Anxiety 
The effect of anxiety on cognitive functioning is thought to be an inverted U function 
where excessively low or high anxiety impairs performance (Gladsjo et al., 1998). 
Anxiety is associated with increased vigilance, surveillance and evaluation of the 
environment for signs of danger. It engages attention and competes with other 
cognitive tasks for resources (Nitschke, Heller & Miller, 2000). Anxiety in the form 
of worry is thought to utilise the central executive and the articulatory loop and 
therefore decrease the efficiency of performing other cognitive tasks that utilise these 
resources (Eysenck & Calvo, 1992). 
There are some studies that have assessed the effects of non-clinical anxiety on 
neuropsychological functioning (Lezak et al., 2004) although most have focused on 
specific anxiety disorders (Airaksinen, Larsson & Forsell, 2005). While clinical 
anxiety is often detrimental to cognitive functioning (Waldstein, Ryan, Jennings, 
Muldoon & Manuck, 1997), studies of non-clinical anxiety have provided largely 
non-significant findings on tests of verbal short term memory and learning (Kizilbash, 
Vanderploeg & Curtiss, 2002), executive functioning, processing speed, verbal 
fluency (Temple, Horner & Taylor, 2004), verbal long term memory and attentional 
capacity (Waldstein et al., 1997). 
Haemochromatosis and Cognitive Functioning — Evidence from Case Studies 
Case studies have investigated patients with haemochromatosis and altered cognitive 
functioning, although most have involved patients with advanced disease and 
additional complications. Victor, Adams and Cole (1965) collected medical data on 
patients with hepatic coma, a common outcome of untreated haemochromatosis and 
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Wilson's Disease (Jones & Hedley-Whyte, 1983), and noted anecdotally that many 
patients demonstrated cognitive impairments. They reported that patients exhibited 
slowed responses, an incapacity to form ideas or think logically, poor attention span, 
impaired short-term memory and lack of insight into their deficits. Many presented as 
apathetic and disinterested, although some were impulsive and agitated. Symptom 
severity varied between patients — some were clearly disoriented while others' 
impairments only became evident through psychometric testing. 
Victor et al. (1965) administered the WAIS and the WMS to 15 of their 27 patients. 
Deficits were noted on all tests, both verbal and visual, with severe impairments 
found for measures of abstract reasoning and retention of new information. Cerebellar 
damage was evident from gait problems, lurching, clumsiness and frequent falls. 
Tremor, ataxia, slowed speech and poor volume control were also common (Victor et 
al., 1965). On investigation, parenchymal damage was evident in the cerebral cortex, 
white matter, basal ganglia, cerebellar cortex and dentate nucleus. Victor et al. 
concluded that the observed cognitive problems were secondary to extensive liver 
damage rather than dur to iron or other metals accumulating in the brain. 
Jones and Hedley-Whyte (1983) reported two case studies of people with both 
haemochromatosis and AD. Their patients were treated for haemochromatosis, one 
with venesection and one with a low protein diet, and symptoms of dementia 
subsequently improved. Symptoms then worsened when patients' protein limit was 
increased. Post-mortem examination was performed for one patient and Alzheimer 
type II astrocytes were found in the cerebral cortex and the cerebellar dentate nucleus. 
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Astrocytes in the caudate, putamen and dentate nuclei contained iron (Jones & 
Hedley-Whyte, 1983). No psychometric test scores were reported for these cases. 
Conclusions and Suggestions for Further Research 
People with haemochromatosis frequently complain of cognitive problems, 
particularly memory problems. Iron overload and oxidative damage impairs the 
functioning of various organs such as the liver, heart and pancreas and evidence 
indicates that this may also occur in the brain. Brain iron overload is noted in diseases 
such as Hallervorden-Spatz Syndrome, Parkinson's Disease, Huntington's Disease 
and Alzheimer's Disease and is implicated in their pathogenesis and progression. The 
hippocampus, basal ganglia and white matter are particularly susceptible to iron-
mediated damage and therefore motor functions, memory, learning, information 
processing speed and attention are likely to be affected. 
Mechanisms for iron absorption and transport are still being discovered and additional 
research is required to elucidate how iron overload occurs within the body, 
particularly the brain. Brain iron absorption and transport is complicated due to the 
many different brain regions and changing developmental requirements. It is likely 
that the brain utilises several methods of iron transportation and distribution. 
It appears that no researchers to date have investigated cognitive functioning in 
haemochromatosis with the exception of case studies. These studies have frequently 
been confounded by comorbid diseases and alcohol abuse and have failed to consider 
the impact of mood, fatigue and pain on cognitive functioning. More comprehensive 
investigations including sensitive neuropsychological tests, exclusion of participants 
26 
with possible confounding problems and a large sample of participants with a 
matched control group are required to clarify whether objective evidence exists for 
cognitive processing difficulties associated with haemochromatosis. 
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Empirical Study 
Are Cognitive Processing Problems associated 
with Hereditary Haemochromatosis? 
Abstract 
Many people with haemochromatosis report decreased cognitive functioning as a 
symptom of their disease. Increasing evidence suggests that iron accumulation within 
the brain is involved in the pathogenesis and progression of many neurodegenerative 
diseases, particularly Alzheimer's Disease. Case studies have noted cognitive deficits 
in patients with haemochromatosis, however these patients have had advanced disease 
and other complicating factors such as comorbid conditions and alcohol dependence, 
making interpretation of findings difficult. The present study aimed to assess whether 
people with haemochromatosis demonstrated deficits in cognitive processes such as 
memory, information processing speed, attention and learning compared to matched 
controls. These processes are sensitive to mild and diffuse brain damage and are 
therefore most likely to be affected by iron-induced oxidative stress. The study 
included a large sample of haemochromatosis patients, a matched control group and a 
comprehensive neuropsychological test battery. Other factors such as depression and 
fatigue that are common symptoms of haemochromatosis and have been found to 
impact on cognitive functioning were also measured. The results of a MANOVA 
including all cognitive test scores indicated that participants with haemochromatosis 
have reduced cognitive functioning compared to controls. Individual t tests revealed 
significant deficits in motor speed as assessed by Information Processing Speed Task 
A. All other test scores showed no significant deficits compared to controls. Factors 
such as years since diagnosis, time since venesection and symptom severity were not 
significantly correlated with cognitive test scores, however future research is required 
to elucidate whether fluctuations in iron levels or other aspects of the disease 
influence cognitive processing. 
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Introduction 
Many people who have haemochromatosis report cognitive problems - particularly 
problems with memory - as a symptom of their disease. While these complaints have 
often been dismissed by health professionals as resulting from fatigue or depression, 
there is evidence that iron-mediated damage within the brain may be responsible. 
Hereditary haemochromatosis is an inherited disease in which the body absorbs too 
much dietary iron. It is caused by a mutation in the HFE gene named C282Y and 
affects approximately 1 in 200 people (Pietrangelo, 2003). The mutation causes 
excess iron to be absorbed and deposited in various organs, leading to oxidative 
damage and cell death. Common symptoms include fatigue and a general feeling of 
illness, liver and heart problems, abdominal pain, bronzed skin, type 2 diabetes and 
arthritis. These symptoms usually appear in the third to fifth decade of life. 
Iron is involved in oxygen transport, cell differentiation (Lieu, Heiskala, Peterson & 
Yang, 2001), glucose metabolism, and the synthesis of neurotransmitters, myelin and 
DNA (Pinero & Connor, 2000). Iron also has the ability to cause "the conversion of 
hydrogen peroxide into free-radical ions that attack cellular membranes, protein and 
DNA" (Emerit, Beaumont & Trivin, 2001, p. 333). Iron-binding proteins such as 
transferrin and ferritin act as safe transport and storage systems and normally prevent 
this conversion. However, when these become overloaded, free iron can travel within 
the bloodstream to various organs in the body (Emerit et al., 2001). 
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Because the body's capacity to eliminate iron is limited, iron absorption is carefully 
controlled. Iron uptake is increased when a person is anaemic and decreased when 
levels are sufficient. People with haemochromatosis have a defective regulatory 
system that causes iron absorption to occur at 2-3 times the normal rate, even when 
iron stores are sufficient (Pietrangelo, 2003). How the mutation in FIFE translates to 
increased absorption is largely unknown and it is possible that other genes are also 
involved (Fleming & Sly, 2002; Wood, 2002). 
Iron is first absorbed within the intestine by enterocytes that are programmed to 
register iron levels prior to maturation. These cells receive information regarding 
current iron stores and needs from various independent sources (Andrews, 1999) and 
alter their rate of absorption accordingly. Iron is then transported across the lining of 
the intestine into the bloodstream. 
Iron can cross the blood brain barrier and is essential to normal brain function. The 
brain naturally has a high iron requirement, consistent with its high energy needs 
(Pinero & Connor, 2000). Iron deficiency is associated with cell loss and decreased 
function within the brain and has significant and long-lasting effects on cognitive 
functioning (Burdo & Connor, 2002). Common consequences of iron deficiency 
include problems with "...cognition, motor function, dopamine-related activities and 
myelinogenesis..." (Connor, Menzies et al., 2001, p. 119). 
The brain is negatively affected by iron overload. Excess brain iron has been 
associated with the pathogenesis and progression of Frederich's Ataxia, Huntington's 
Disease, Hallervorden-Spatz Syndrome, Parkinson's Disease and Alzheimer's 
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Disease (Burdo & Connor, 2002; Thompson, Shohan & Connor, 2001). Imaging 
studies show signs of increased iron in the basal ganglia and the choroid plexus in 
people with haemochromatosis (Burdo & Connor, 2002). 
Case studies have indicated that cognitive deficits are often related to untreated 
haemochromatosis (Jones & Hedley-Whyte, 1983; Victor, Adams & Cole, 1965). 
Common problems associated with haemochromatosis include slowed responses, an 
incapacity to form ideas or think logically, poor attention span, impaired short-term 
memory and lack of insight into deficits. Testing with the WAIS and the WMS have 
revealed deficits on all tests, both verbal and visual, with severe impairments found 
for measures of abstract reasoning and retention of new information (Victor et al., 
1965). 
Cognitive deficits have also resolved when iron levels are reduced by venesection 
(Cutler, 1994; Milder, Cook, Stray & Finch, 1980; Tandon, Taroch & Falcon, 1988), 
iron-chelating drugs and/or a low-protein diet (Jones & Hedley-Whyte, 1983). 
Increased iron and haemochromatosis has also been related to brain damage. Victor et 
al. (1965) found parenchymal damage in the cerebral cortex, white matter, basal 
ganglia, cerebellar cortex and dentate nucleus of their patients. Jones and Hedley-
Whyte (1983) noted Alzheimer type II astrocytes in the cerebral cortex and the 
cerebellar dentate nucleus of one of their patients. 
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Few of these case studies have used comprehensive psychometric test batteries and 
the patients have had advanced disease, concurrent health problems and/or histories of 
alcohol abuse, making findings difficult to attribute to iron overload. 
Many iron overload support groups list cognitive problems as a symptom of 
haemochromatosis. The Haemochromatosis Society Australia, Canadian 
Hemochromatosis Society, The Haemochromatosis Society UK, Iron Overload 
Diseases Association, and Iron Disorders Institute all include memory problems in 
their haemochromatosis literature. 
If brain iron overload does negatively impact on cognitive functioning then it is 
important to isolate these effects from other confounding factors. Alcohol intake, 
medication use and other physical problems can be controlled for by excluding such 
participants, however other factors such as depression and fatigue are common 
symptoms of haemochromatosis and are therefore more difficult to control. 
Pain and fatigue are common symptoms of haemochromatosis. Pain has been found to 
negatively impact on processing speed, attention and memory (Hart, Martelli & 
Zasler, 2000; DiStefano & Radanov, 1995), although some studies have found no 
differences between individuals with chronic pain and controls (Bell, Primeau, Sweet 
& Lofland, 1999). Chronic fatigue has been associated with deficits in working 
memory (Deluca et al., 2004), executive functioning (Marcel, Komaroff, Faioli, 
Kornish & Albert, 1996), learning and information processing speed (Busichio, 
Tiersky, Deluca & Natelson, 2004). 
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Depression is a frequently reported symptom of haemochromatosis, and anxiety is 
common during adjustment to diagnosis. Clinical depression has a negative impact on 
cognitive processes, particularly mental flexibility and control (Veiel, 1997). Greater 
severity leads to greater cognitive deficits (Airaksinen, Larsson, Lundberg, & Forsell, 
2004; Elderkin-Thompson et al., 2003). Anxiety places a greater burden on the 
articulatory loop and central executive and competes successfully with other cognitive 
tasks involving these functions (Eysenck & Calvo, 1992). 
The cognitive processes that are most likely to be affected by haemochromatosis, 
whether by iron overload or by emotional and physical factors, are those that are 
sensitive to brain damage. Information processing speed, attention, memory and 
learning are frequently affected by mild and diffuse brain damage (Lezak, Howieson 
& Loring, 2004). 
Information processing speed underlies other cognitive functions such as attention, 
learning and memory (Gronwall & Sampson, 1974). It is often compromised by 
diffuse brain damage and is therefore likely to involve many areas of the brain 
(Felmingham et al., 2004; Gronwall & Sampson, 1974). Attention is primarily a 
function of the prefrontal cortex, although different aspects are mediated by different 
areas, and some elements may be impaired while others remain intact (Rogers, 2000). 
Learning is defined as the ability to acquire knowledge and memory is the ability to 
retain it (Lieberman, 2004). Memory involves the encoding, storage and retrieval of 
experience and can be divided into short-term and long-term systems. It is thought 
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that STM is mediated by the frontal lobes and LTM is consolidated by the 
hippocampal structures and then stored in a distributed fashion in the neocortex 
(Liberman, 2004). Baddeley (1986) extended the role of STM to include processes 
such as problem solving and decision-making and named it 'working memory'. This 
is divided into verbal and visuo-spatial memory (Della Salla, Gray, Baddeley, 
Allamano & Wilson, 1999). 
The aforementioned cognitive processes are all interdependent; therefore tests that 
aim to measure one process inevitably measure aspects of some or all of them. 
Neuropsychological tests vary in their degree of sensitivity and specificity (Dobbs, 
Dobbs & Kiss, 2001). Various test batteries have been developed to maximise both 
sensitivity and specificity in measuring a wide range of cognitive processes. Some of 
the most commonly used batteries include the Wechsler Adult Intelligence Scale III 
(WAIS III) (Wechsler, 1997), which measures a range of intellectual abilities in both 
verbal and non-verbal domains, and the Wechsler Memory Scale III (WMS 
(Wechsler, 1997), which measures various aspects of memory. The Adult Memory 
and Information Processing Battery (AM:1PB) (Coughlan & Hollows, 1985) also 
measures various aspects of memory and learning in both visual and verbal domains 
(Lezak, 1995). However, its norms are based on a British population, which is more 
similar to the Australian population than American norms (Clark et al., 2004) and it 
includes a measure of information processing speed that is more specific than than 
other batteries as it requires less visual scanning and motor output than other similar 
tasks, and includes an adjustment for motor speed (Vlaar & Wade, 2003), making it 
ideal for populations with potential motor speed problems such as haemochromatosis. 
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As well as batteries for neuropsychological testing, there are specific tests designed 
for more detailed examinations of a particular function. For example, the 
Paced Auditory Serial Addition Task (PASAT) (Gronwall & Sampson, 1974) is a 
widely used and highly sensitive test of attention and information processing speed 
(Lockwood, Linn, Szymanski et al., 2004) and the Visual Patterns Test is a relatively 
pure measure of visual short-term memory (Della Salla, Gray, Baddeley, Allamano 
&Wilson, 1999). 
The effects of iron overload on cognitive functioning need to be separated from an 
individual's natural cognitive strengths and weaknesses. Tests such as the National 
Adult Reading Test can measure pre-morbid cognitive abilities (Spreen & Strauss, 
1998) and differentiate between 'real' deficits, caused by brain damage, and 
premorbid abilities that include natural strengths and weaknesses. 
In summary, untreated haemochromatosis causes iron-mediated damage that affects 
the heart, liver, pancreas and joints, resulting in a variety of clinical symptoms. 
Research has also demonstrated that iron crosses the blood brain barrier and is found 
in excessive amounts in the brains of people with neurodegenerative diseases such as 
Parkinson's disease and Alzheimer's disease. It is still debated whether excess iron 
accumulates in the brains of people with haemochromatosis, and if it does, whether 
this impacts on cognition and behaviour. Case studies have indicated that dementia, 
disorientation, motor problems such as ataxia and memory problems occur in 
conjunction with haemochromatosis, particularly in severe cases, however whether 
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this occurs more generally in people with haemochromatosis, and whether it is due to 
excess iron in the brain or other secondary effects of the disease is unknown. 
There have been no studies to date investigating cognitive processes in people with 
haemochromatosis using a large sample, a control group and a comprehensive 
neuropsychological test battery. This may be partly due to the belief that the cognitive 
problems experienced by people with haemochromatosis are due to secondary effects 
of the disease such as fatigue and depression. 
The present study aims to investigate whether people with haemochromatosis have 
poorer performances on measures of memory, learning, attention and information 
processing compared to matched healthy controls and if so, whether a particular 
pattern of deficits exists. It also aims to discover whether these problems are 
associated with a primary cause (excess iron) or with secondary factors such as pain, 
fatigue, anxiety and/or depression. 
Based on the limited research in this area, the main hypotheses are: 
1 - Participants with haemochromatosis may have significantly lower scores than 
controls on tests of memory and learning. The most sensitive tests, and therefore the 
most likely to show group differences in this domain, include Design Learning and 
List Learning. 
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2 — Participants with haemochromatosis may have significantly lower scores than 
controls on tests of attention and working memory. The PASAT is the most likely test 
to show significant differences as this is the most sensitive measure in this domain. 
3 — People with haemochromatosis may have significantly lower scores on tests of 
information processing speed than controls, as measured by Information Processing 
Task A. Information processing speed is particularly sensitive to mild and diffuse 
brain damage. 
4 - Deficits in cognitive processes may be due to iron overload and not specifically to 
anxiety/depression or fatigue. 
Method 
Participants 
Participants were 40 adults with a diagnosis of hereditary haemochromatosis (HH), 
aged from 19 to 79 years, including 21 males and 19 females. Diagnoses of 
haemochromatosis were confirmed by participants' general practitioner and based on 
genetic testing. Forty healthy controls were included and the groups were matched for 
gender, age and years of education (details of age, education, etc. are shown in Table 
1). Participants with a diagnosed mental illness, a major health problem not related to 
haemochromatosis or who were taking medications or other substances that are 
known to interfere with cognitive processes were excluded from the study. Carriers 
(one BYE gene mutation) were also excluded. In all cases participation was voluntary 
and no payment was offered for participation. 
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Participants were recruited through newspaper advertisements, fliers handed out at the 
ambulatory ward of the Royal Hobart Hospital, a television news story, an iron 
overload disorders support group in Hobart and through personal acquaintance. 
Materials 
Participants were assessed with the following measures: 
Personal Data Sheet 
This contained participants' basic demographic and medical details (Appendix A). 
Haemochromatosis Symptom Severity Rating Scale 
A visual analogue scale of 18 common haemochromatosis symptoms was used to 
measure symptom severity. A space was included for participants to note symptoms 
that did not appear on the list. Instructions specified that a mark at the beginning of 
the line (at zero) indicated no effect, and a mark at the end of the line (at one hundred) 
indicated that the symptom was 'as bad as I can imagine' (Appendix B). 
Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983). 
This 14-item self-report questionnaire measures anxiety and depression in non-
clinical samples. Seven items are dedicated to measuring anxiety and seven to 
depression. It was designed to differentiate between symptoms of physical disorders 
and mood by excluding items that could be associated with both, such as fatigue or 
appetite (Pincus, Fraser & Pearce, 1998). The HADS is quick to complete and has 
good face validity. Both the anxiety and depression scales have good reliability and 
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validity and are sensitive to change (Snaith & Zigmond, 1994). Scores for anxiety and 
depression are calculated separately and range from 0-21 (Appendix B). 
Brief Fatigue Inventory (Hann, Jacobsen, Azzarelo et al., 1998). 
This 10-item self-report measure focuses on the intensity and duration of fatigue and 
its impact on daily activities (Hann et al., 1998). The questionnaire was modified to 
make it more specific to haemochromatosis and cognitive functioning; an item 
relating to mobility was removed and two items relating to cognitive processes were 
added. Scores range from 0-100 (Appendix B). 
National Adult Reading Test (NART) (Nelson, 1982). 
This test was used to estimate participants' premorbid intellectual abilities. 
Participants read aloud 50 irregularly spelled words presented in order of increasing 
difficulty. Test scores correlate highly (0.85) with 'g' or the general factor of 
intelligence (Nelson & Willison, 1982) and can be used to estimate WAIS-R full-
scale IQ scores (Spreen & Strauss, 1998). The NART is one of the most reliable 
measures of its type; reading ability is robust as it is generally preserved in people 
with mild to moderate dementia (Spreen & Strauss, 1998) and depression (Nelson & 
Willison, 1982) (Appendix B). 
Adult Memory and Information Processing Battery (AMIPB) (Coughlan & Hollows, 
1985). 
This battery of tests includes various memory, learning and information processing 
tasks. The AMIPB is standardised on a UK sample with four age norm groups ranging 
from 18-75. Scores can be used to estimate standard scores or percentiles. 
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Correlations between subtests are minimal, suggesting that they tap into different 
skills and abilities (Coughlan & Hollows, 1985). Each of the subtests included in the 
battery are sensitive to cognitive dysfunction (Coughlan & Hollows, 1985). The 
following subtests from the battery were included in the study: 
Story Recall 
This is primarily a measure of immediate and long-term verbal memory. Participants 
listen to a short story and then repeat what they remember both immediately and 30 
minutes after presentation (Appendix C). 
List Learning 
This subtest measures verbal rote learning and memory as well as susceptibility to 
interference. Participants listen to and then recall a list of 15 unrelated words. After 5 
trials a new (interference) list is presented and recalled, then participants are asked to 
recall the original list (Appendix C). 
Figure Recall 
This is primarily a measure of immediate and long-term visual memory. Participants 
copy a complex figure and then draw it from memory immediately and after 30 
minutes (Appendix C). 
Design Learning 
This subtest measures visual rote learning, memory and susceptibility to interference. 
Participants are presented with a design on a 4x4 grid of dots. After 10 seconds of 
viewing, they reproduce the design on a blank grid. After 5 trials, a new (interference) 
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design is presented and recalled and then participants recall the original design 
(Appendix C). 
Information Processing Speed Task A. 
This task measures ability to mentally engage in a repetitive, speed-based task that 
requires sustained attention. Participants are given a sheet of paper with 105 rows of 
five two-digit numbers and asked to cross out the second highest number in each row. 
After completing a ten-item sample, they are given four minutes to complete as many 
of the rows as they can. Participants then complete a simple cancellation task 
(crossing out rows of 11's) for 20 seconds and this score is used to adjust for motor 
speed. This test is particularly sensitive to cerebral dysfunction (Coughlan & Hollows, 
1985) (Appendix C). 
The Visual Patterns Test (VPT) (Della Sal/a, Gray, Baddeley & Wilson, 1997). 
This test measures short-term visual memory. Participants are presented with a grid 
on a card in which half of the squares are black. The grids range from 2x2 to 5x6 
(Della Salla et al., 1999) in increasing difficulty. Participants are shown each card for 
3 seconds and asked to reproduce the pattern on a blank grid of the same dimensions. 
When a participant fails to correctly reproduce three consecutive grids of one size, the 
test is discontinued. The VPT has two parallel forms. Version A, used in this study, 
has a test-retest reliability of .75. It is considered a comparatively pure measure of 
visual memory as it has a minimal spatial component (Della Salla et al., 1999) (Two 
examples of medium-difficulty designs are shown in Appendix C). 
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Paced Auditory Serial Additions Test (PASAT) (Gronwall, 1977; Gronwall & 
Sampson, 1974) 
This test is primarily considered a test of information processing but also measures 
working memory capacity, executive control and sustained and divided attention 
(Lockwood et al., 2004). A recorded tape is played in which 60 single-digit numbers 
are presented at set intervals (2.0 seconds in this study). Participants are required to 
progressively add the last two presented numbers. The test has comprehensive norms 
for adult populations and is a sensitive measure of subtle, diffuse damage (Spreen & 
Strauss, 1998). It is widely used to assess a variety of neurological problems. The test 
has high reliability and validity (Lezak, 1995). Scores range from 0-60 (Appendix C). 
Wechsler Adult Intelligence Scale — III (WAIS III) (Wechsler, 1997). 
This test battery measures intellectual ability and is used as a diagnostic tool for 
neurological disorders (Wechsler, 1997). The various subscales measure verbal and 
visual-spatial reasoning, memory, attention and information processing speed. Two of 
the subtests from the WAIS are included in this study — Digit Span and Letter-
Number Sequencing. Raw scores can be converted into standard scores and/or 
percentiles. 
Digit Span 
This subtest measures verbal short-term memory capacity, sequencing ability and 
verbal working memory. It requires participants to listen to and repeat strings of digits 
of increasing length. Participants perform digits forwards - repeating the sequence in 
order, and digits backwards — repeating the sequence in reverse order. The digits 
backwards task places a greater burden on working memory. The subtest has good 
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reliability, with test-retest estimates from .83 -.89 depending on age group (Wechsler, 
1997). 
Letter Number Sequencing 
This test is a sensitive measure of verbal working memory. Participants are required 
to listen to strings of jumbled numbers and letters of increasing length and repeat 
them in a re-organised sequence; letters in alphabetical order followed by numbers in 
numerical order. Reliability estimates are good, with test-retest estimates of .70 -.80 
depending on age group (Wechsler, 1997). 
Procedure 
Ethics approval was obtained from the Southern Tasmania Health and Medical 
Human Research Ethics Committee (ref H0007519). A pilot study was first 
undertaken with four participants - two with a diagnosis of haemochromatosis and 
two controls. The aims of the pilot study were to determine the presentation order of 
the tests and ensure that participants understood the questionnaires. No problems were 
noted in the pilot study. 
Participants with haemochromatosis were asked to complete the assessment at least 
two weeks post-venesection, as fatigue is common for a few days after treatment. A 
small amount of participants were having venesection weekly and these participants 
were tested just prior to venesection. The mean period of time post-venesection was 
10 weeks (range 1-36). Participants were tested at a time suitable to them, usually in 
the morning when they felt most alert. Each block of tests took approximately half an 
hour to complete and a ten-minute break was given between blocks. 
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Assessments were conducted in a consulting room either at the University Psychology 
Clinic or at the Department of Psychiatry at the Royal Hobart Hospital. Participants 
who lived in the North of the state were visited in their homes. 
Participants read the information sheet and signed the consent form (see Appendix D) 
before completing the Personal Data Sheet and the Haemochromatosis Symptoms 
Rating Scale, Brief Fatigue Inventory and the HADS. 
The NART was administered prior to a block of primarily verbal or visual-spatial 
subtests. Participants were then given a break before completing the second block of 
subtests. One block consisted of (in order) Stories subtest, List Learning, Digit Span, 
Letter Number Sequencing and then Delayed Recall of the Stories subtest. The other 
block included Complex Figure, Visual Patterns Test, Design Learning, Paced 
Auditory Serial Addition Test, Information Processing Task A and then the Delayed 
Recall of the Complex Figure subtest. The blocks were administered in 
counterbalanced order. 
Design and Data Analysis 
This study employed a between groups design using independent samples ( tests to 
assess between-group differences for self-report variables and a MANOVA to assess 
between-group differences for cognitive variables (Tabacknick & Fidel!, 2001). 
Cognitive variables were further analysed using independent samples t tests. 
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Pearson Product-Moment correlations were used to investigate the relationships 
between self-report and cognitive variables to see whether specific self-report 
variables negatively impacted on cognition. 
A power analysis was conducted using a standard methodology (Lenth, n.d.) and a 
sample of 40 participants in each group was considered adequate. An alpha level of 
.01 was chosen for correlations and t tests for cognitive variables as a large number of 
measures were included, increasing the risk of Type 1 errors. An alpha level of .05 
was chosen for t tests of self-reported variables as this is the conventional value 
recommended for statistical tests (Tilley, 1994). 
Results 
Self-report measures 
The means and standard deviations for each of the self-report variables are shown in 
Table 1. 
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Table 1 
Means and standard deviations (in parentheses) for self-report participant variables 
Self-Report Variable Haemochromatosis Control 
Age 54.2 (11.4) 54.3 (10.9) 
Education Level 11.8 (2.7) 12.8 (2.6) 
NART score 104.0 (9.0) 105.8 (7.1) 
Haemochromatosis Symptom Score 360.7 (230.9) 223.9 (166.3) 
Brief Fatigue Inventory Score 31.1 (22.6) 22.3 (18.6) 
Anxiety (HADS) Score 6.4 (3.9) 5.7 (3.5) 
Depression (HADS) Score 4.5 (3.9) 2.8 (3.2) 
Years Since Diagnosis (HH only) 4.7 (4.3) 
Weeks Since Venesection (HH only) 10.0 (8.8) 
A significant difference was noted between the two groups for self-reported 
haemochromatosis symptom severity t(78) = 3.04, p < .05. Participants with 
haemochromatosis reported significantly higher symptom severity than controls. 
There was also a significant difference noted between groups for self-rated depression 
1(78) = 2.19, p < .05. Participants with haemochromatosis reported higher rates of 
depression, although both groups' scores were well below the cut-off for clinical 
depression, where 'mild depression' scores are 8-10 (Snaith & Zigmond, 1994). 
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Relationship between self-report and cognitive measures 
Pearson Product-Moment correlations were performed to investigate whether the self-
reported variables were related to cognitive test scores. This data is shown in Table 2 
(see Appendix E). 
A significant positive correlation was found between level of education and delayed 
story recall (r = .33). Depression had a significant negative effect on Complex Figure-
percentage retained (r = -.30). A significant negative correlation was found between 
symptom severity and Design Learning trials A1-A5. The remaining self-report scores 
were not significantly correlated with cognitive test scores. 
Many significant correlations were also noted between self-report variables (see Table 
2). 
Cognitive Measures 
The means and standard deviations for the cognitive test results are presented in Table 
3. All scores are given as percentiles, with the exception of List Learning percentage 
lost and Design Learning percentage lost. These scores were calculated by the 
formula A5 — A6 /A5 x 100 and are measures of percentage of words/lines lost after 
the interference task was presented. 
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Table 3 
Means and standard deviations (in parentheses) of cognitive variables for 
participants with and without haemochromatosis 
Cognitive Test Score Haemochromatosis 
N = 40 
Control 
N = 40 
Story Recall (Immediate Recall) 48.5 (28.4) 46.8 (28.7) 
Story Recall (Delayed Recall) 45.7 (27.6) 44.0 (30.8) 
Digit Span 44.4 (20.3) 55.3 (27.1) 
Letter Number Sequencing 47.2 (22.9) 55.7 (24.6) 
Paced Auditory Serial Addition Test 37.0 (10.1) 41.1 (10.3) 
List Learning Trials 1-5 43.4 (27.5) 45.8 (30.1) 
List Learning Percentage Lost in Recall 20.2 (13.7) 19.9 (14.2) 
Complex Figure Copy 65.6 (18.9) 69.8 (10.3) 
Complex Figure Immediate Recall 75.8 (21.0) 69.2 (21.9) 
Complex Figure Delayed Recall 72.0 (22.3) 68.8 (24.3) 
Design Learning Trials 1-5 45.0 (29.7) 56.2 (31.2) 
Design Learning Percentage lost in Recall 15.7 (25.1) 17.8 (24.7) 
Visual Patterns Test 44.8 (22.8) 40.6 (23.0) 
Information Processing Motor Speed 41.1 (29.4) 62.0 (23.3) 
Information Processing Adjusted Score 61.7 (25.9) 69.6 (27.4) 
A MANOVA was initially performed to investigate overall differences between the 
two groups. The result was significant, Pillai's Trace = .985, F(15, 47) =200.10, p < 
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.01. Participants with haemochromatosis performed more poorly on measures of 
cognitive processing than controls. 
Independent samples t tests were performed to assess between-group differences for 
the cognitive test scores. 
A significant difference was found for motor speed as measured by information 
processing Task A 1(78) = -3.51, p < .01. The haemochromatosis group was 
significantly slower than the control group on this simple speed-based cancellation 
task. No other significant differences were found between the two groups for 
cognitive test scores. 
Because Digit Span scores approached significance, 1(77) = -2.02, p <.05, scores were 
divided into Digits Forwards and Digits Backwards, as the two components are 
proposed to measure slightly different abilities (Lezak, 1995). 
There was a non-significant difference between groups on both tasks. The 
haemochromatosis group performed slightly better than the control group on digits 
forwards, recalling a mean score of 6.57 digits compared to 6.51 digits for the control 
group, 1(1,72) = .19, p = .85. The control group performed better than the 
haemochromatosis group on digits backwards, recalling a mean of 4.95 digits 
compared to 4.46 for the haemochromatosis group, t(1,72) = 1.90, p = .06. 
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Discussion 
This study aimed to investigate whether people with haemochromatosis demonstrated 
deficits on measures of attention, information processing speed, learning and memory 
compared to healthy controls. Consistent with the limited research in this field, it was 
hypothesised that people with haemochromatosis would perform more poorly than 
controls in these cognitive domains. This hypothesis was supported, as participants 
with haemochromatosis achieved significantly lower scores than controls on the 
cognitive tests as a whole. 
More specifically, hypothesis 1 was that people with haemochromatosis would have 
significantly lower scores on tests of memory and learning and that this would most 
likely be demonstrated in test results from Design Learning and List Learning. This 
hypothesis was not supported, as there were no significant differences any measures 
of learning and memory when the test scores were analysed individually. 
Hypothesis 2 was that people with haemochromatosis would have significantly lower 
scores than controls on tests of attention and working memory, and that this would be 
most evident on scores from the PASAT. This hypothesis was not supported, as there 
were no significant between-group differences on measures of attention and working 
memory when the tests were analysed individually. There was a trend, however, for 
people with haemochromatosis to perform more poorly on Digit Span. This finding 
will be further discussed below. 
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Hypothesis 3 was that people with haemochromatosis would achieve significantly 
lower scores on tests of information processing speed than controls, as measured by 
Information Processing Task A. This hypothesis was partially supported. There was 
not a significant difference between groups for information processing speed after an 
adjustment was made for motor speed. However, motor speed itself was significantly 
slower in participants with haemochromatosis than controls. 
Hypothesis 4 was that any deficits in cognitive processes would not be due 
specifically to anxiety/depression or fatigue. This hypothesis was for the most part 
supported as correlations between cognitive test scores and self-reported variables 
such as fatigue, anxiety and depression were generally non-significant. However, 
there were three exceptions for self-reported depression, which will be discussed 
below. 
The evidence in the literature for impaired cognitive functioning in people with 
haemochromatosis was mainly based on physiological data and anecdotal evidence. 
The few studies that have investigated cognitive functioning in people with 
haemochromatosis did not include control groups and few reported 
neuropsychological test data. Therefore, it is difficult to compare the results of this 
study with those of previous studies. 
The cognitive deficits in the haemochromatosis group were minor and generalised, as 
it was only when scores from all cognitive tests were combined that a significant 
difference between the groups could be detected. There was a small between-group 
difference for each cognitive measure and these were in the same direction, with few 
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exceptions, indicating that there is no specific pattern of deficits associated with 
haemochromatosis, but rather a generalised reduction in attention, memory, learning 
and information processing speed. 
There was a significant difference in motor speed between the groups. This is not 
surprising given the basal ganglia is the target of iron overload in many neurological 
diseases (Burdo & Connor, 2002). Neuroimaging studies have indicated that iron 
levels are elevated in the basal ganglia (Burdo & Connor, 2002; Connor et al, 2001; 
Pinero & Connor, 2000), which is responsible for the initiation and coordination of 
movement (Lezak et al., 2004). Case studies of people with haemochromatosis have 
noted psychomotor retardation (Milder et al., 1980), ataxia, jerky movements, rigidity 
and poor hand coordination (Jones & Hedley-Whyte, 1983) as symptoms of 
haemochromatosis. Patients with Wilson's Disease, in which copper levels are 
elevated within the basal ganglia, also display slow motor speed responses in test 
situations (Littman, Medalia, Senior & Scheinberg, 1995). However, another 
explanation for slowed motor speed in haemochromatosis may be a high prevalence 
of arthritis, which is a common symptom of haemochromatosis and is particularly 
prevalent in the hands (Milder et al., 1980). 
There was a trend for participants with haemochromatosis to perform more poorly 
than controls on the Digit Span subtest. Further analysis indicated that digits 
backwards, rather than digits forwards, best differentiated the two groups although 
there was not a significant difference between digits forwards and backwards scores. 
Digit Span is a measure of attentional capacity, as increasing amounts of information 
are stored in working memory. Digits Backwards includes an additional component to 
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Digits Forwards in that participants manipulate as well as retain information by 
rearranging the digits upon recall. Digit Span is considered to be a less sensitive 
measure than the PASAT, however the two tests measure different aspects of 
attention and working memory. The PASAT measures information processing speed 
and attention and is not a measure of capacity as it only requires participants to add 
two digits at a time, whereas Digit Span is primarily a measure of capacity. Letter-
Number Sequencing is also similar to Digit Span, particularly the backwards 
component, as it also measures working memory capacity and has a manipulation 
component and no significant difference was noted for this test. Another measure of 
visual capacity, the Visual Patterns Test, also showed no significant between-group 
differences. It may be that this finding is due to Type 1 error rather than a real 
between-groups difference. 
A significant positive correlation was found between level of education and delayed 
story recall (r = .33) and there was a trend for education to be positively correlated to 
immediate story recall. It is common for education to have a positive influence on test 
scores in nearly all domains (Lezak, 1995), although many tests, such as the Visual 
Patterns Test, include adjustments for education that aim to reduce its effect on test 
results (Della Salla et al., 1999). Symptom severity was significantly related to 
performance on the Design Learning trials Al-A5. Participants with less severe 
haemochromatosis symptoms performed better on the learning trials than those with 
more severe symptoms, however retention (percentage retained) was not affected. 
Depression had a significant negative effect on Complex Figure percentage retained 
which measures the amount of information lost between immediate and delayed recall 
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(r = -.30). There was also a non-significant trend for depression to negatively impact 
on Story Recall immediate and delayed scores. These findings are consistent with 
those reported in Veiel's (1997) review where approximately 15% of depressed 
individuals performed significantly more poorly than controls on tests involving recall 
of complex figures and stories (Veiel, 1997). 
Significant correlations were also noted between various self-report variables. 
Participants who reported high levels of haemochromatosis symptoms tended to 
report higher levels of anxiety, depression and fatigue. As the symptoms of each of 
these constructs tend to overlap, this result was expected. 
Participants with haemochromatosis reported significantly higher symptom severity 
than controls, indicating that they were affected by symptoms of the disease. They 
also reported significantly higher depression scores. However, both groups reported 
low depression scores compared to clinical samples and neither group was classified 
as clinically depressed (Snaith & Zigmond, 1994). Because all participants who 
reported clinical psychological or physical health problems were excluded from the 
study, the effects of these on cognitive test scores were expected to be minimal. 
There are several possible reasons why few significant differences were found 
between participants with haemochromatosis and controls on the cognitive measures. 
One possibility is that the cognitive tests were not sensitive enough to pick up subtle 
differences between the groups. However, the measures that were used are considered 
to be highly sensitive to brain damage and are able to determine subtle and diffuse 
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damage in cases such a mild concussion. Therefore, they should have been able to 
detect real between-group differences if they existed. 
The choice of statistical tests or number of participants may have affected the power 
to detect real differences between the groups. However, a power analysis determined 
that 40 participants in each group would be sufficient to detect any real between-
group differences. Because of the lack of previous research, this study aimed to 
measure a wide range of cognitive processes and as such, many cognitive test scores 
were included in analysis. To reduce the likelihood of Type 1 errors, an alpha level of 
.01 was nominated. This may have increased the likelihood of Type 2 errors, however 
only one cognitive test (Digit Span) reached significance at the less stringent .05 alpha 
level. 
Another possibility is the selection of participants. Participants were volunteers and 
opted to complete the tests knowing that their cognitive functions were being 
measured. Two participants in the haemochromatosis group found the test battery too 
difficult and chose not to continue. Their data was not included in the study. There 
may have been other potential participants with haemochromatosis who felt that their 
cognitive processes were impaired and decided not to volunteer for the study due to 
the potential for failure on the tests. 
The haemochromatosis group was also heterogenous — the disease has a wide range of 
symptoms, participants had been diagnosed for varying amounts of time and were at 
different stages of treatment. All haemochromatosis participants had no other major 
health problems and most were currently experiencing few symptoms of 
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haemochromatosis. However, some participants had been diagnosed early and would 
have had elevated iron levels for only a short period of time, while others had been 
diagnosed late in life, experienced severe symptoms and had had severely elevated 
iron levels. Iron levels were not measured in this study, so it is difficult to explore the 
relationships between iron levels and cognitive performance. Efforts were made to 
elucidate whether time since diagnosis, time since venesection and symptom severity 
influenced test scores, and no significant correlations were found. However, it 
remains that some participants may have experienced real problems with cognition 
while others didn't, just as some haemochromatosis patients have arthritis or heart 
problems and others don't. Analysing group results as a whole may have masked the 
scores of some impaired individuals. 
The control group also consisted of volunteers and most of these were known to the 
researcher. The control group and the haemochromatosis group both performed below 
expected levels on tests of verbal and visual-spatial learning. Participants in the 
control group may have been more anxious about their performance as they were 
familiar with the experimenter, despite being reassured that all test scores were 
confidential, and this may have impacted on their performance on some of the 
cognitive tests. 
This study did not include a measure of pain and therefore could not investigate its 
effects on cognitive functioning. It has been well documented that severe pain can 
impair cognitive functions, particularly information processing speed, attention and 
memory (DiStefano & Radanov, 1995; Hart et al., 2000). It is unlikely that the 
majority of haemochromatosis participants experienced pain severe enough to impact 
66 
on cognitive functioning, however investigating the influence of pain on motor speed, 
particularly, may have helped to elucidate whether this significant finding was due to 
cognitive factors or arthritis. The study also did not include a test of effort. Rohling, 
Green, Allen and Iverson (2002) suggest that using tests of effort and symptom 
validity tests help to differentiate between reported and real deficits in cognitive 
functioning and it would be useful to include these measures in future research. 
Further research is required to investigate a number of questions raised by this study. 
Is motor speed impaired in people with haemochromatosis and is it due to the 
cognitive control of motor functioning or to physical factors such as pain or swollen 
joints? Is there a capacity problem in working memory in people with 
haemochromatosis, as suggested by the results from the Digit Span subtest? Do 
factors such as previous and current iron levels, treatment regime or constellation of 
symptoms relate to cognitive abilities? Do carriers, who have elevated iron levels 
without overt symptoms, experience cognitive problems? 
A study using repeated measures, for example pre and post venesection, rather than a 
control group could avoid the recruitment problems experienced in this study and 
hence the difficulty of participants' familiarity with the experimenter. If a control 
group was required, using a researcher who was blind to participants' diagnostic 
status may also control for possible confounding effects that may have occurred in 
this study. 
It also remains that the significant findings of this study may be due to an aspect of 
the disease other than increased iron levels in the brain. The liver is one of the first 
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points of iron overload in haemochromatosis due to its naturally high iron content. 
Liver disease can impair attention and processing speed while having little impact on 
memory and conceptual abilities (Lezak et al., 2004). A more detailed analysis of 
symptoms in future studies may help to separate other possibilities from that of 
increased brain iron. 
In conclusion, in 1980 Milder et al. noted in a review of haemochromatosis patients 
that "Neurologic symptoms have impressed us more than would be suggested by the 
general literature.. .but have received little attention since then." (Milder et al., 1980, 
p. 44). This study aimed to address this gap in the literature by assessing cognitive 
functioning in people with haemochromatosis using a comprehensive 
neuropsychological test battery and a matched control group. Significant between-
group differences were found with haemochromatosis patients achieving lower scores 
overall for the cognitive tests. When the tests were analysed individually, the most 
prominent difference was in motor speed, with Digit San showing a trend towards 
significance. Whether these differences are due to iron overload within the brain or 
some other factor is still unknown and further research is required to confirm and 
further investigate the current findings. 
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Personal Data Sheet 
Date: 	/ 	/ 	 Participant ID number: 	  
Name: 	  
Address: 
Postcode: 
Phone: Home 	 Work 	 Other 	  
Date of Birth: 	/ 	/ 
Gender (Please circle) 	Male / Female 
Level of Education Achieved 	  
Are you suffering from a psychological disorder? (Please circle) Yes / No 
If 'Yes' please specify: 	  
Does this condition affect your memory or thinking? 
Do you have any physical health problems other than Haemochromatosis? 
(Please circle) 	Yes / No 
If 'Yes' please specify: 	  
Does this affect your memory or thinking? 
Are you taking any medications? (Please circle) Yes / No 
If 'Yes' please specify: 	  
Have you stopped taking any medication in the last 3 months (Please circle) 
Yes / No 
If yes, please specify: 	  
77 
Have you been diagnosed with Haemochromatosis? 
If Yes 
When was this diagnosis made? 	  
Who diagnosed you? 	  
Are you currently having treatment? 	Yes / No 
Please outline treatment type and frequency (e.g. venesections every 
three months) 
When was your last venesection? 	  
As you know we need to contact the medical practitioner who diagnosed you 
with HH to confirm this diagnosis, if you consent to this (as per consent form) 
please provide the following information. 
Name of Medical Practitioner 
Address 
Phone Contact: 
If No 
Have you been tested for Haemochromatosis (that is has a Dr checked 
your iron levels or done a genetic test)? Yes / No 
Has anyone in your family been diagnosed with Haemochromatosis? 
Yes/No 
78 
Appendix B 
Self-Report and Demographic Data forms: 
Haemochromatosis Symptom Severity Rating Scale 
Hospital Anxiety and Depression Scale 
Brief Fatigue Inventory - Revised 
National Adult Reading Test 
79 
The following items from the list above have been removed for copyright or proprietary 
reasons:
Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983)
Brief Fatigue Inventory (Hann, Jacobsen, Azzarelo et al., 1998)
National Adult Reading Test (NART) (Nelson, 1982)
Haemochromatosis Symptom Severity Rating Scale 
Please rate to what extent you experience the following symptoms by placing 
a mark on the line (from 0 - not at all affected to 100— as bad as I can 
imagine) 
o 	 100 
Lethargy 
Heart Problems 
Forgetfulness 
Skin Lesions 
Liver Problems 
Loss of Body Hair 
Irritability 
Arthritis 
Depression 
Itchiness 
Inability to Concentrate 	  
Abdominal Discomfort 	  
Anxiety 
Bronzed Complexion 	  
Loss of Sex Drive 
Diabetes 
Weakness 
Weight Loss 
Other (Please Specify) 
-  
-  
-  
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Appendix C 
Cognitive Tests 
Story Recall 
List Learning lists A and B 
Figure Recall — Complex Figure 
Design Learning Designs A and B 
Information Processing Speed Task A 
Visual Patterns Test 
Paced Auditory Serial Addition Test 
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The following items from the list above have been removed for copyright or 
proprietary reasons:
Story Recall; List Learning lists Aand B; Figure Recall - Complex Figure; Design 
Learning Designs A and B; Information Processing speed Task A. The source for 
all thes tests is: Adult Memory and Information Processing Battery (AMIPB)
(Coughlan & Hollows, 1985)
Also removed is:
The Visual Patterns Test (VPT) (Della Sal/a, Gray, Baddeley & Wilson, 1997), 
and
Paced Auditory Serial Additions Test (PASAT) (Gronwall, 1977; Gronwall & 
Sampson, 1974)
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UNIVERSITY 
OF TASMANIA 
School of Psychology 
Information Sheet 
Does Haemochromatosis affect memory? 
Chief Investigators: Lisa Gilroy, lain Montgomery & Clive Skilbeck 
Research Student: Gayle McElwee 
Purpose of the Study: 
People who have genetic haemochromatosis store too much iron in their bodies. Excess iron can 
be deposited in various organs in the body such as the liver, heart and joints. This excess iron is 
toxic and causes damage to these organs. It is thought that excess iron can also cross the blood-
brain-barrier and affect thought processes such as memory. The purpose of this study is to 
investigate whether people with haemochromatosis achieve significantly lower scores on 
measures of memory, learning, attention and/or processing speed, compared to a control group 
who do not have a diagnosis of haemochromatosis. 
Criteria for Inclusion: 
We are looking for 40 people who are aged 18+ who have a definite diagnosis of 
haemochromasotis (this will need to be confirmed by your medical practitioner). We also need 40 
people who do not have a diagnosis of haemochromatosis and are otherwise healthy. We will try. 
to match the two groups by age, gender and years of education. 
Study Procedures: 
The assessment will take place in a private, quiet room at the University Psychology Clinic, 
which is located at the University of Tasmania, School of Psychology (Annexe), Churchill 
Avenue, Sandy Bay. The date and time of the appointment, which has been discussed and 
tentatively booked, will be confirmed by phone or email one day prior to the assessment session. 
If required, further directions to the clinic will be given at this time. 
You will be asked to read the information sheet and sign the consent form, thehfill in three 
questionnaires relating to your health. 
You will then participate in a series of tests that assess aspects of cognitive ability; memory, 
attention, learning and processing speed. 
When the cognitive assessment is completed, you will be given brief feedback about your 
performance. You will also have a chance to ask questions. 
The entire session should take just over an hour. The cognitive/memory assessment should take 
60 minutes and completing questionnaires 10 minutes. 
Possible Benefits: 
The results of this study should indicate whether people with haemochromatosis 
suffer from memory/attention problems. If this is the case, then teaching these people 
Private Bag 30 Hobart 
Tasmania Australia 7001 
Telephone (03) 6226 2237 
Facsimile (03) 6226 2883 
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strategies to improve their abilities may be beneficial. This study may also help to raise public 
awareness of haemochromatosis and its possible effects, which may lead to a greater emphasis on 
early screening and prevention. 
Confidentiality: 
Your responses to the questionnaires and the results from your cognitive assessment will not be 
• identifiable by name. All questionnaires and cognitive test results will be kept in a locked filing 
cabinet within the Psychology Department at the University of Tasmania for five years, after 
which they will be destroyed. 
Freedom to Reficse or Withdraw: 
As you are a volunteer in this study, you are able to refuse to participate or withdraw from the 
procedure at any time, for any reason, without prejudice. 
Withdrawl of a participant from the Project by the Investigators: 
If at any time it seems evident that you are unduly distressed by any procedure, the assessment 
process will be discontinued. 
Approval: 
This project has received ethical approval from the Southern Tasmania Social Sciences Human 
Research Ethics Committee. 
Contact Persons: 
Investigator: Gayle McElwee. ph 62261808 or email mcelweeg,@utas.edu.au  
Supervisor: Lisa Gilroy. ph 62264886, or email ljg,ilroy@utas:edu.au 
Supervisor: lain Montgomery. ph  6226-3846, or email Iain.Montgomerv@utas.edu.au  
Supervisor: Clive Skilbeck. ph 6226-7459, fax: 6226-2883, or email Clive.Skilbeck@utas.edu.au  
Concerns or Complaints: 
You may contact the 'Contact Persons' or the Southern Tasmania Social Sciences Human 
Research Ethics Committee: 
Chair — Associate Professor Gino Del Pont Ph 62262078 
Or Executive Officer — Amanda McAully. Ph 62262763 
Results of Investigation: Individual results will not be available, as questionnaire data is not 
identified by name. However, group data from the study will be available on request, and will be 
available on the University homepage at the completion of the study. Link: www.utas.edu.au  
Please keep a copy of this form so that you can contact the above people if necessary. 
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 UNIVERSITY 
OF TASMANIA I School of Psychology 
Consent Form 
Does Haemochromatosis affect memory? 
Investigators: Lisa Gilroy, lain Montgomery, Clive Skilbeck, Gayle McElwee 
Statement By Participant: 
I have read and understood the 'Information Sheet' for this study. 
The nature and possible effects of the study have been explained to me. 
I understand that the study involves the following procedures: 
• Filling in three questionnaires relating to my health (approx 10 minutes). 
• Completing a series of tests designed to measure my thought processes including my memory, 
processing speed, learning and attention (approx 60 minutes). 
I understand that the content of the questionnaires may be sensitive, as they relate to my perceptions 
of my health. The results of the memory assessment may also be disappointing if they are not parallel 
with my expectations. 
understand that I will not be given detailed feedback regarding my results on tests concerning my 
memory, processing speed, learning and attention, but rather general brief feedback. 
I understand and consent to my medical practitioner being contacted to confirm my diagnosis of 
haemochromatosis (if applicable). 
I have been informed that the results of the study may not be of any direct benefit to my medical — 
management. 
Any questions that I have asked have been answered to my satisfaction. 
I agree that research data gathered for the study may be published provided that I cannot be identified 
as a participant. 
I understand that research data will be securely stored in a locked filing cabinet in the School of 
Psychology on University of Tasmania premises for a period of at least 5 years, after which it will be 
destroyed. 
I agree to participate in this investigation and I understand that I may withdraw at any time without 
prejudice. 
-ne of participant: Signature: 	 Date: 
tement by researcher: 
ive explained this study and the implications of participation in it to this volunteer and I believe that the 
sent is informed and that he/she understands the implications of participation. 
96 PrivailtdUg 30 Hobart 
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re of researcher: 	 Signature: 
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Table 2 
Correlations between demographic, self-report and cognitive variables 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
1 -.24 .08 -.06 -.26 -.10 -.14 .06 .12 -.15 .16 .20 -.24 -.01 .04 .27 -.09 .06 .26 .14 -.11 -.10 -.17 .05 -.04 
2 -.13 .14 .07 .16 .21 .03 .01 .06 -.01 -.17 -.05 .02 .04 -.05 .04 .07 .26 .14 .09 .09 .19 .02 -.19 
3 .17 .09 -.17 .03 .07 -.03 -.22 .28 .33* .18 .08 -.02 .10 -.04 -.13 -.02 .11 .11 -.12 .10 .18 -.02 
4 .08 .23 .04 -.06 .02 -.05 .11 .10 .18 .20 .06 .22 .02 .05 .01 .09 .00 -.01 .17 .03 -.02 
5 .01 -.04 0.11 0.13 0.12 .06 .07 -.06 .22 .20 -.14 .14 -.41 .20 .27 .04 .36 -.03 -.04 -.01 
6 -.04 -.11 -.13 -.12 .06 .07 -.06 .22 .20 -.14 .12 -.41* .20 .27 .04 .40 -.03 -.04 -.01 
7 .71* .48* .58* -.14 -.17 .00 -.16 .05 -.10 .03 -.15 -.12 -.18 -.26* .11 -.12 -.15 -.16 
8 .47* .65* -.10 -.11 -.09 -.23 -.04 -.09 -.06 -.15 -.14 -.22 -.21 -.03 -.24 -.12 -.19 
9 .42* -.11 -.11 -.09 -.18 -.10 .10 -.09 .09 -.16 -.09 -.19 .02 -.00 -.04 -.16 
10 -.26 -.27 -.06 -.14 -.05 -.11 .08 -.04 -.17 -.31* -.15 .06 -.02 -.13 .05 
11 .92* -.06 .05 .08 -.36* -.08 .03 .11 .16 .01 .14 .13 .07 -.04 
12 -.02 .04 .04 .30* -.05 .07 .10 .18 .10 .08 .15 .07 -.05 
13 •41* •39* .12 .07 -.03 -.11 .09 .17 -.01 .11 .14 .12 
14 •43* .29* .09 .16 -.09 .07 .14 -.17 .18 .28 .37* 
15 .02 .13 .12 -.14 -.09 .10 .10 .17 .15 .29* 
16 -.12 .10, .13 .20 -.01 -.04 -.11 .22 .20 
17 .07 - .04 .09 .00 .14 .05 .03 .10 
18 -.02 -.10 -.06 -.32* .01 .07 .21 
19 .81* .30* -.15 -.02 .07 -.11 
20 .37* -.14 .17 .08 -.04 
21 -.33* .25 .23 .19 
22 -.03 -.06 -.00 
23 .12 .22 
24 .30* 
25 
*p< .01 
00 
Key to Table 2 
1 Sex 
2 Age 
3 Education 
4 NART scores converted into IQ scores 
5 Years since diagnosis 
6 Weeks since venesection 
7 Haemochromatosis Symptom Severity score 
8 Brief Fatigue Inventory score 
9 Anxiety score (HADS) 
10 Depression score (HADS) 
11 Story Recall Immediate recall score 
12 Story Recall Delayed recall score 
13 Digit Span score (forwards & backwards combined) 
14 Letter Number Sequencing score 
15 PASAT score 
16 List learning Al-AS score 
17 List Learning percentage retained score 
18 Complex Figure copy score 
19 Complex Figure Immediate recall score 
20 Complex Figure Delayed recall score 
21 Design Learning Al-A5 score 
22 Design Learning percentage retained score 
23 Visual Patterns Test score 
24 Information Processing Task A Speed score 
25 Information Processing Task A Adjusted Score (adjusted for motor speed) 
